Guiso Nicole
Institut Pasteur, unité Prévention et Thérapie Moléculaires des Maladies Humaines, 25 rue du Dr Roux, 75724 Paris Cedex 15, France.
Ther Adv Vaccines. 2013 Jul;1(2):59-66. doi: 10.1177/2051013613481348.
Universal pertussis vaccination has successfully decreased pertussis mortality and morbidity in childhood. However, despite intensive vaccination of young children, pertussis remains a major public health problem in both developing and industrialized regions. Recent epidemics in California and Australia demonstrated that the agent of the disease is still circulating. They also revealed several aspects that must not be neglected concerning vaccine-preventable diseases. Indeed, pertussis is one of the oldest vaccine-preventable bacterial diseases, so can provide a good illustration of all of the aspects associated with the need for surveillance after the introduction of vaccination. (i) The type of vaccine: two types of pertussis vaccine, whole cell and acellular, inducing different types of immunity are now used around the world. (ii) The vaccine strategy, the vaccine coverage and the duration of vaccine immunity: pertussis epidemics provide evidence that 90% of the infants must be vaccinated, vaccination must be sufficiently early and both vaccine-induced immunity and natural infection-induced immunity to pertussis wane with time indicating that pertussis is not only a pediatric disease. (iii) The agents of the disease, Bordetella pertussis and Bordetella parapertussis: the intensive vaccination of young infants modified the herd immunity, controlled bacteria similar to the vaccine strains but not all, revealing polymorphism of the agents of the disease evidencing the importance of continuing their isolation and their surveillance as well as monitoring their antibiotic resistance. (iv) The diagnosis of the disease: the epidemics showed the importance of specific diagnostic techniques that are easy to use by medical laboratories and the availability of the reagents required. (v) Communication with the public, the health authorities and the health providers: any changes of vaccine type, vaccine strategy, characteristics of the disease, and biological diagnosis must be associated with appropriate communication with the public and training of healthcare workers. Currently, herd immunity needs to be increased by introducing vaccine boosters for adolescents and adults to protect the most vulnerable group: unvaccinated newborns.
全球百日咳疫苗接种已成功降低了儿童百日咳的死亡率和发病率。然而,尽管对幼儿进行了密集接种,但百日咳在发展中地区和工业化地区仍是一个重大的公共卫生问题。加利福尼亚州和澳大利亚最近的疫情表明,该疾病的病原体仍在传播。它们还揭示了一些与疫苗可预防疾病相关的不可忽视的方面。事实上,百日咳是最古老的疫苗可预防细菌性疾病之一,因此可以很好地说明接种疫苗后监测需求的所有相关方面。(i)疫苗类型:目前全球使用两种类型的百日咳疫苗,全细胞疫苗和无细胞疫苗,它们诱导不同类型的免疫。(ii)疫苗策略、疫苗覆盖率和疫苗免疫持续时间:百日咳疫情证明,90%的婴儿必须接种疫苗,接种必须足够早,而且疫苗诱导的免疫力和自然感染诱导的对百日咳的免疫力都会随时间减弱,这表明百日咳不仅是一种儿科疾病。(iii)疾病病原体,百日咳博德特氏菌和副百日咳博德特氏菌:对幼儿的密集接种改变了群体免疫,控制了与疫苗菌株相似但并非全部的细菌,揭示了疾病病原体的多态性,证明了持续分离和监测它们以及监测其抗生素耐药性的重要性。(iv)疾病诊断:疫情表明了易于医学实验室使用的特定诊断技术以及所需试剂可用性的重要性。(v)与公众、卫生当局和医疗服务提供者的沟通:疫苗类型、疫苗策略、疾病特征和生物学诊断的任何变化都必须与与公众的适当沟通以及医护人员的培训相关联。目前,需要通过为青少年和成年人引入疫苗加强剂来提高群体免疫力,以保护最脆弱的群体:未接种疫苗的新生儿。